CTOs on the Move

Treasure Coast Radiation Oncology, Pa

www.tcropa.com

 
Treasure Coast Radiation Oncology, Pa is a Stuart, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.tcropa.com
  • 2107 SE Ocean Blvd
    Stuart, FL USA 34996
  • Phone: 772.781.5780

Executives

Name Title Contact Details

Similar Companies

Advanced Environmental Testing And Abatement

Advanced Environmental Testing And Abatement, Inc is a Waterloo, IA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Piedmont Medical Laboratory

Piedmont Medical Laboratory is a Winchester, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

JPT Peptide Technologies GmbH

JPT Peptide Technologies GmbH is a Acton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Folio Conversant

Folio Conversant is the premier provider of research services and biospecimen solutions. We offer an extensive array of quality biospecimens, particularly Human tissue and biofluids, supported by comprehensive laboratory and analytical services. Science does not stand still. Our goal is to become a key partner in supporting your team`s research and development in order to accelerate new diagnostic and therapeutic options for patients.

Vaxcyte

Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Vaxcyte`s lead candidate, VAX-24, is a 24-valent, broad-spectrum pneumococcal conjugate vaccine being developed for the prevention of invasive pneumococcal disease. Vaxcyte is re-engineering the way highly complex immunizations are made through modern synthetic techniques, including advanced chemistry and the XpressCFᵀᴹ cell-free protein synthesis platform, exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company`s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits. Vaxcyte`s pipeline also includes VAX-XP, a PCV with an expanded breadth of coverage of greater than 30 strains; VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; and VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease. Vaxcyte is driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked.